A chimeric human/dog-DNA vaccine against CSPG4 induces immunity with therapeutic potential in comparative preclinical models of osteosarcoma
Authors:
Open Access
- 12 June 2023
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 31 (8) , 2342-2359
Abstract
No abstract availableKeywords
Funding Information
- Compagnia di San Paolo
- Ministero della Salute (RF2013-02359216)
- Fondazione Umberto Veronesi (4298-2021)
- Fondazione Ricerca Molinette (8893/5)
This publication has 54 references indexed in Scilit:
- PDGFs and PDGFRs in canine osteosarcoma: New targets for innovative therapeutic strategies in comparative oncologyThe Veterinary Journal, 2013
- CD44 enhances tumor formation and lung metastasis in experimental osteosarcoma and is an additional predictor for poor patient outcomeJournal of Bone and Mineral Research, 2012
- Identification of Myeloid Derived Suppressor Cells in Dogs with Naturally Occurring CancerPLOS ONE, 2012
- CSPG4, a potential therapeutic target, facilitates malignant progression of melanomaPigment Cell & Melanoma Research, 2011
- Xenogeneic Murine Tyrosinase DNA Vaccine for Malignant Melanoma of the Digit of DogsJournal of Veterinary Internal Medicine, 2011
- Osteosarcoma incidence and survival rates from 1973 to 2004Cancer, 2009
- Comparative Oncology TodayVeterinary Clinics of North America: Small Animal Practice, 2007
- Responses of mice immunized with a DNA vaccine encoding carcinoembryonic antigen (CEA)Vaccine, 2006
- Human High Molecular Weight Melanoma-Associated Antigen Mimicry by Mouse Anti-Idiotypic Monoclonal Antibody MK2-23: Enhancement of Immunogenicity of Anti-Idiotypic Monoclonal Antibody MK2-23 by Fusion with Interleukin 2Cancer Research, 2005
- Quantitative real-time PCR protocol for analysis of nuclear receptor signaling pathwaysNuclear Receptor Signaling, 2003